Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Announce Earnings of $0.49 Per Share

Equities analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) will report earnings per share of $0.49 for the current quarter, according to Zacks. Eleven analysts have made estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.75 and the lowest is $0.31. Neurocrine Biosciences posted earnings of $0.43 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 14%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $1.86 per share for the current financial year, with EPS estimates ranging from $1.55 to $2.41. For the next fiscal year, analysts anticipate that the company will post earnings of $3.40 per share, with EPS estimates ranging from $2.15 to $5.05. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). The firm had revenue of $310.60 million during the quarter, compared to analyst estimates of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 31.3% on a year-over-year basis. During the same period last year, the company posted $0.33 EPS.

Several analysts have weighed in on NBIX shares. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $125.00 to $126.00 and gave the company an “overweight” rating in a report on Monday, April 4th. The Goldman Sachs Group upgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $115.00 price objective on the stock in a research report on Thursday, February 24th. Piper Sandler downgraded Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $114.00 to $94.00 in a research report on Thursday, March 3rd. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Thursday, April 28th. Finally, Zacks Investment Research upgraded Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 21st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $112.13.

Neurocrine Biosciences stock traded down $5.73 during trading hours on Friday, hitting $79.55. The stock had a trading volume of 1,094,739 shares, compared to its average volume of 660,754. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.02 and a quick ratio of 3.83. The stock has a market capitalization of $7.60 billion, a price-to-earnings ratio of 110.49 and a beta of 0.70. Neurocrine Biosciences has a 1-year low of $71.88 and a 1-year high of $108.01. The stock’s fifty day moving average is $93.13 and its two-hundred day moving average is $88.01.

In other news, Director Gary A. Lyons sold 15,000 shares of the stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $92.76, for a total value of $1,391,400.00. Following the completion of the sale, the director now owns 208,697 shares in the company, valued at $19,358,733.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William H. Rastetter sold 10,728 shares of the stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $94.93, for a total value of $1,018,409.04. Following the completion of the sale, the director now owns 34,022 shares of the company’s stock, valued at approximately $3,229,708.46. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,743 shares of company stock valued at $4,232,771. Insiders own 4.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Whittier Trust Co. grew its stake in Neurocrine Biosciences by 102.8% during the 4th quarter. Whittier Trust Co. now owns 290 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares in the last quarter. IndexIQ Advisors LLC acquired a new stake in Neurocrine Biosciences during the 1st quarter valued at approximately $27,000. Moors & Cabot Inc. acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $30,000. KB Financial Partners LLC acquired a new stake in Neurocrine Biosciences during the 4th quarter valued at approximately $33,000. Finally, Orion Capital Management LLC acquired a new stake in Neurocrine Biosciences during the 4th quarter valued at approximately $34,000. Hedge funds and other institutional investors own 93.21% of the company’s stock.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories